National Cancer Institute CRADA
Executive Summary
NCI is seeking pharmaceutical/biotech company to enter into a Cooperative Research & Development Agreement for the anti-Tac(Fv)- PE38 single chain immunotoxin as a therapy for leukemias or lymphomas, NCI announces in Oct. 7 Federal Register. The recombinant immunotoxin fuses the combining site of the anti-Tac monoclonal antibody, which reacts with human interleukin-2 receptors found in many types of leukemias, lymphomas and activated human T cells, to the recombinant form of Pseudomonas exotoxin "in which the cell binding domain of the toxin has been removed," the notice states. Anti-Tac(Fv)-PE38 preclinicals indicate that the toxin can produce complete remission of human tumors in mice without significant toxicities. Anti-Tac(Fv)-PE38 also has been shown to be "very active in killing activated human monocytes and may be useful in treating autoimmune diseases," NCI says. Statements of interest in the CRADA are due on or before Jan. 5, 1994. Questions to NCI's Ira Pastan, MD: (301) 496-4797; FAX (301) 402-1344.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth